CryoCapCell, a Paris, France-based company that develops and markets technologies for high-pressure vitrification, raised €1.5m in funding.
The Quadrivium 1 seed capital fund, managed by Seventure Partners, made the investment.
The company intends to use the funds to Thanks continue the development and commercial deployment of its technologies
Led by Xavier Heiligenstein, co-founder, CryoCapCell has developed correlative microscopy technologies using high-pressure vitrification, which prevents the alteration of biological structures. The company is initially targeting research laboratories using correlative microscopy, an approach that aims to understand the relationship between a biological structure and its function, an indispensable process, particularly in the study of tumours.